CA3053116A1 - Methods for the detection and treatment of lung cancer - Google Patents
Methods for the detection and treatment of lung cancer Download PDFInfo
- Publication number
- CA3053116A1 CA3053116A1 CA3053116A CA3053116A CA3053116A1 CA 3053116 A1 CA3053116 A1 CA 3053116A1 CA 3053116 A CA3053116 A CA 3053116A CA 3053116 A CA3053116 A CA 3053116A CA 3053116 A1 CA3053116 A1 CA 3053116A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- lung cancer
- sftpb
- subject
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 443
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 442
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 442
- 238000000034 method Methods 0.000 title claims abstract description 355
- 238000001514 detection method Methods 0.000 title claims abstract description 109
- 238000011282 treatment Methods 0.000 title claims description 42
- 239000000427 antigen Substances 0.000 claims description 333
- 108091007433 antigens Proteins 0.000 claims description 333
- 102000036639 antigens Human genes 0.000 claims description 333
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 308
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 308
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 308
- 108010036226 antigen CYFRA21.1 Proteins 0.000 claims description 293
- 239000000090 biomarker Substances 0.000 claims description 282
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 223
- 102100023123 Mucin-16 Human genes 0.000 claims description 223
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 220
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims description 209
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims description 209
- 239000012472 biological sample Substances 0.000 claims description 180
- NQNXERHVLXYXRO-UHFFFAOYSA-N Diacetylspermine Chemical compound Cl.Cl.CC(=O)NCCCNCCCCNCCCNC(C)=O NQNXERHVLXYXRO-UHFFFAOYSA-N 0.000 claims description 130
- 230000000391 smoking effect Effects 0.000 claims description 92
- 239000000523 sample Substances 0.000 claims description 81
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 77
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 77
- 230000035945 sensitivity Effects 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 201000011510 cancer Diseases 0.000 claims description 63
- 239000003153 chemical reaction reagent Substances 0.000 claims description 54
- 238000004611 spectroscopical analysis Methods 0.000 claims description 53
- 238000005481 NMR spectroscopy Methods 0.000 claims description 51
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 claims description 51
- 210000004369 blood Anatomy 0.000 claims description 44
- 239000008280 blood Substances 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 238000003556 assay Methods 0.000 claims description 34
- 238000005100 correlation spectroscopy Methods 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 31
- 239000002207 metabolite Substances 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 26
- 238000001356 surgical procedure Methods 0.000 claims description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 25
- 210000002381 plasma Anatomy 0.000 claims description 25
- 238000004949 mass spectrometry Methods 0.000 claims description 23
- 238000002405 diagnostic procedure Methods 0.000 claims description 22
- 238000003018 immunoassay Methods 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 22
- 239000002131 composite material Substances 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 20
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 18
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 18
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 claims description 17
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 17
- 208000009956 adenocarcinoma Diseases 0.000 claims description 15
- 238000007619 statistical method Methods 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 13
- 238000001959 radiotherapy Methods 0.000 claims description 13
- 238000002626 targeted therapy Methods 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 10
- 238000012163 sequencing technique Methods 0.000 claims description 10
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 238000013179 statistical model Methods 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940044683 chemotherapy drug Drugs 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 5
- 230000002494 anti-cea effect Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000012474 protein marker Substances 0.000 claims description 3
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000004590 computer program Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 122
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 187
- 238000012216 screening Methods 0.000 description 32
- 238000010200 validation analysis Methods 0.000 description 25
- 238000013058 risk prediction model Methods 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 15
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 238000012549 training Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 238000007477 logistic regression Methods 0.000 description 10
- 235000019504 cigarettes Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 description 8
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 201000008261 skin carcinoma Diseases 0.000 description 4
- 238000012306 spectroscopic technique Methods 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- -1 antibodies Proteins 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 208000016508 combined lung carcinoma Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BBNHCUBQEQJHIG-FZZJNMCHSA-N 1-[(8Z,11Z,14Z)-icosatrienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C BBNHCUBQEQJHIG-FZZJNMCHSA-N 0.000 description 1
- IHNKQIMGVNPMTC-RUZDIDTESA-N 1-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C IHNKQIMGVNPMTC-RUZDIDTESA-N 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100032202 Cornulin Human genes 0.000 description 1
- 206010063599 Exposure to chemical pollution Diseases 0.000 description 1
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
- 101000920981 Homo sapiens Cornulin Proteins 0.000 description 1
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 108091002660 WAP Four-Disulfide Core Domain Protein 2 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000000117 blood based biomarker Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940087158 gilotrif Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940052129 zykadia Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Probability & Statistics with Applications (AREA)
- Physiology (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456731P | 2017-02-09 | 2017-02-09 | |
| US62/456,731 | 2017-02-09 | ||
| PCT/US2018/017704 WO2018148600A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3053116A1 true CA3053116A1 (en) | 2018-08-16 |
Family
ID=63107741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053116A Pending CA3053116A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12405274B2 (enExample) |
| EP (2) | EP3580560B1 (enExample) |
| JP (1) | JP7311417B2 (enExample) |
| KR (2) | KR102630885B1 (enExample) |
| CN (2) | CN117368475A (enExample) |
| CA (1) | CA3053116A1 (enExample) |
| ES (1) | ES2995959T3 (enExample) |
| WO (1) | WO2018148600A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102630885B1 (ko) | 2017-02-09 | 2024-01-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료 방법 |
| US20220260573A1 (en) * | 2019-07-29 | 2022-08-18 | Biomark Cancer Systems Inc. | Method of discriminating lung cancer patients |
| US20230213521A1 (en) * | 2020-04-28 | 2023-07-06 | Luxembourg Institute Of Health (Lih) | Biomarkers for detection of lung cancer |
| CA3191405A1 (en) * | 2020-09-01 | 2022-03-10 | Ali Ya KHAMMANIVONG | Predictive diagnostic test for early detection and monitoring of diseases |
| CN112147099A (zh) * | 2020-09-22 | 2020-12-29 | 范庆坤 | 一种m蛋白紫外分光检测法 |
| EP4222287A4 (en) * | 2020-10-02 | 2024-12-18 | Board of Regents, The University of Texas System | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER |
| EP4357782A1 (en) * | 2022-10-18 | 2024-04-24 | MU Bioteknik Aktiebolag | Protein biomarker panel for the diagnosis of colorectal cancer |
| CN115575636B (zh) * | 2022-11-22 | 2023-04-04 | 杭州广科安德生物科技有限公司 | 一种用于肺癌检测的生物标志物及其系统 |
| CN116593702B (zh) * | 2023-05-11 | 2024-04-05 | 杭州广科安德生物科技有限公司 | 一种肺癌的生物标志物以及诊断系统 |
| CN118983078B (zh) * | 2024-08-15 | 2025-03-25 | 立本医疗器械(成都)有限公司 | 基于ptr-tof-ms的肺癌筛查模型构建方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2610806T3 (es) | 2005-12-22 | 2017-05-03 | Abbott Molecular Inc. | Métodos y combinaciones de marcadores para la detección de la predisposición al cáncer de pulmón |
| US20080133141A1 (en) * | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| EP2153232A1 (en) * | 2007-05-18 | 2010-02-17 | Duke University | Serum biomarkers for the early detection of lung cancer |
| CA2798441A1 (en) * | 2010-05-07 | 2011-11-10 | Abbvie Inc. | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor |
| US20120087860A1 (en) * | 2010-05-24 | 2012-04-12 | Marek Malecki | Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags |
| US20130078642A1 (en) | 2010-06-03 | 2013-03-28 | Porto Conte Richerche S.R.L. | Biomarkers for lung neuroendocrine tumors |
| CN102321760A (zh) * | 2011-08-26 | 2012-01-18 | 泸州医学院附属医院 | 一种非小细胞肺癌标志物及应用 |
| US9753043B2 (en) * | 2011-12-18 | 2017-09-05 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| US20140271453A1 (en) * | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods for the early detection of lung cancer |
| US9753037B2 (en) | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| US20150072890A1 (en) * | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| US20160060329A1 (en) | 2014-07-28 | 2016-03-03 | Donald SIN | Compositions and methods for the diagnosis and prognosis of lung cancer |
| CA3029063C (en) | 2015-06-26 | 2023-09-05 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
| JP6903672B2 (ja) | 2016-03-08 | 2021-07-14 | マグアレイ，インコーポレイテッド | 肺癌の診断および治療のための蛋白質と自己抗体バイオマーカー |
| CN105717146B (zh) * | 2016-03-29 | 2018-11-09 | 复旦大学附属中山医院 | 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒 |
| KR102630885B1 (ko) | 2017-02-09 | 2024-01-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료 방법 |
| EP4222287A4 (en) * | 2020-10-02 | 2024-12-18 | Board of Regents, The University of Texas System | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER |
-
2018
- 2018-02-09 KR KR1020197026040A patent/KR102630885B1/ko active Active
- 2018-02-09 CN CN202311117176.0A patent/CN117368475A/zh active Pending
- 2018-02-09 EP EP18752036.6A patent/EP3580560B1/en active Active
- 2018-02-09 JP JP2019542716A patent/JP7311417B2/ja active Active
- 2018-02-09 KR KR1020247002923A patent/KR102827354B1/ko active Active
- 2018-02-09 WO PCT/US2018/017704 patent/WO2018148600A1/en not_active Ceased
- 2018-02-09 CA CA3053116A patent/CA3053116A1/en active Pending
- 2018-02-09 ES ES18752036T patent/ES2995959T3/es active Active
- 2018-02-09 EP EP24204031.9A patent/EP4528741A3/en active Pending
- 2018-02-09 CN CN201880010925.0A patent/CN110291397A/zh active Pending
-
2023
- 2023-03-28 US US18/191,506 patent/US12405274B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12405274B2 (en) | 2025-09-02 |
| US20230314436A1 (en) | 2023-10-05 |
| EP4528741A3 (en) | 2025-04-09 |
| KR102827354B1 (ko) | 2025-06-30 |
| KR102630885B1 (ko) | 2024-01-29 |
| WO2018148600A1 (en) | 2018-08-16 |
| EP3580560B1 (en) | 2024-10-02 |
| EP3580560A1 (en) | 2019-12-18 |
| ES2995959T3 (en) | 2025-02-11 |
| EP3580560A4 (en) | 2020-12-09 |
| US20200025766A1 (en) | 2020-01-23 |
| JP2020510816A (ja) | 2020-04-09 |
| EP4528741A2 (en) | 2025-03-26 |
| JP7311417B2 (ja) | 2023-07-19 |
| KR20190116368A (ko) | 2019-10-14 |
| CN117368475A (zh) | 2024-01-09 |
| CN110291397A (zh) | 2019-09-27 |
| KR20240015172A (ko) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12405274B2 (en) | Methods for the detection and treatment of lung cancer | |
| Rho et al. | Protein and glycomic plasma markers for early detection of adenoma and colon cancer | |
| US20240159753A1 (en) | Methods for the detection and treatment of lung cancer | |
| US20230304993A1 (en) | Circulating tumor cell diagnostics for lung cancer | |
| Roe et al. | Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study | |
| JP2011523049A (ja) | 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー | |
| Marmor et al. | Biomarkers in lung cancer screening: a narrative review | |
| US20180100858A1 (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| CN120188046A (zh) | 鉴定胰腺癌的方法 | |
| CN117831690A (zh) | 检测待测血样异常信号定量的计算机实施方法 | |
| Carbone et al. | Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC | |
| Yu et al. | Elevated serum megakaryocyte potentiating factor as a predictor of poor survival in patients with mesothelioma and primary lung cancer | |
| WO2024107923A1 (en) | Methods for the detection and treatment of lung cancer | |
| Lu et al. | Auxiliary diagnosis of lung cancer on the basis of a serum protein biomarker panel | |
| US12504430B2 (en) | Methods for the detection and treatment of lung cancer | |
| KR20240167655A (ko) | 면역 체크포인트 저해제 단제의 약리 작용과 비교한, 면역 체크포인트 저해제와 병용약으로서의 항암제의 조합의 상대적인 약리 작용의 평가 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 기록 매체, 평가 시스템, 및 단말 장치 | |
| Li et al. | Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study | |
| Du et al. | Prognostic value of combining preoperative immune-inflammatory-nutritional index and tumor biomarkers in gastric cancer patients undergoing radical resection | |
| Tong et al. | Diagnostic value of tumor associated autoantibody panel in early detection of lung cancer in Chinese population: Protocol for a prospective, observational, and multicenter clinical trial | |
| WO2024250906A1 (en) | Methods of detecting lung cancer | |
| WO2024249401A2 (en) | Methods for the detection and treatment of lung cancer | |
| CN116529603A (zh) | 用于检测和治疗肺癌的方法 | |
| WO2025064345A2 (en) | Methods for the detection and treatment of lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230207 |
|
| EEER | Examination request |
Effective date: 20230207 |
|
| EEER | Examination request |
Effective date: 20230207 |
|
| EEER | Examination request |
Effective date: 20230207 |